Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 12/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4322605 | 1.00 | LTA4H (0.52) | LTA4HNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4325898 | 0.89 | LTA4H (0.46) | LTA4HMEN1KMT2A | |
| SCHEMBL4325900 | 0.89 | LTA4H (0.46) | LTA4HMEN1KMT2A | |
| SCHEMBL5169205 | 0.88 | MAOB (0.44) | LTA4H | |
| SCHEMBL4319604 | 0.87 | LTA4H (0.55) | LTA4HNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4319602 | 0.87 | LTA4H (0.55) | LTA4HNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4316756 | 0.87 | MAOB (0.38) | LTA4HRAB9AMEN1KMT2A | |
| SCHEMBL4316758 | 0.87 | MAOB (0.38) | LTA4HRAB9AMEN1KMT2A | |
| SCHEMBL4318290 | 0.84 | LTA4H (0.47) | LTA4HNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4318292 | 0.84 | LTA4H (0.47) | LTA4HNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582656-B2 | Guanidine derivatives and therapeutic uses thereof | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-01 | — | — | US | claimed |
| US-7582656-B2 | Guanidine derivatives and therapeutic uses thereof | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20080004315-A1 | Guanidine Derivatives and Therapeutic Uses Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
| EP-1771428-A1 | GUANIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF | MERCK PATENT GmbH (DE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010422-A1 | GUANIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004315-A1 | Guanidine Derivatives and Therapeutic Uses Thereof | GMPS, GUCY1A2, GUCY1A1 | LTA4H 3247/4885NPC1 1813/4885RAB9A 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.